Seelos Therapeutics Receives European Orphan Drug Designation For SLS 005 Trehalose In Amyotrophic LateralSclerosis ALS

Seelos Therapeutics Receives European Orphan Drug Designation For SLS 005 Trehalose In Amyotrophic LateralSclerosis ALS

By, Admin 1 June 2021

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on thedevelopment of therapies for central nervous system disorders and rare diseases, today announced it has received European OrphanDrug Designation for SLS-005 in amyotrophic lateral sclerosis (ALS) from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP). Under orphan designation in the European Union (EU), Seelos stands to benefit from several incentives such as protocol assistance,reduced regulatory fees and market exclusivity. European guidelines for Orphan Drug Designation are for diseases affecting not morethan five in 10,000 people in the EU.In November, SLS-005 was granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for ALS. SLS-005 waspreviously granted Orphan Drug Designation from the FDA and EMA for Spinocerebellar Ataxia Type 3 (SCA3), Sanfilippo syndrome andOculopharyngeal Muscular Dystrophy (OPMD). SLS-005 has also been granted Fast Track designation from the FDA for OPMD

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!